摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester | 877132-31-5

中文名称
——
中文别名
——
英文名称
imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester
英文别名
ethyl imidazo[1,2-b][1,2,4]triazine-6-carboxylate
imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester化学式
CAS
877132-31-5
化学式
C8H8N4O2
mdl
——
分子量
192.177
InChiKey
DQEMTSZCTIRAGD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    69.4
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester二异丁基氢化铝甲醇乙酸乙酯 作用下, 以 二氯甲烷甲苯 为溶剂, 反应 1.33h, 以12%的产率得到imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde
    参考文献:
    名称:
    [EN] INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
    [FR] INHIBITEURS DE POLYMERASE D'ARN DEPENDANT D'ARN DU VIRUS DE L'HEPATITE C ET COMPOSITIONS ET TRAITEMENT UTILISANT CES INHIBITEURS
    摘要:
    本发明提供了公式(4)的化合物,以及它们的药学上可接受的盐和溶剂化合物,这些化合物可用作肝炎病毒(HCV)聚合酶酶的抑制剂,并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含公式(4)的化合物、其药学上可接受的盐和溶剂的药物组合物。此外,本发明提供了制备公式(4)化合物的中间体化合物和方法。
    公开号:
    WO2006018725A1
  • 作为产物:
    描述:
    1,2,4-三嗪-3-胺3-溴丙酮酸乙酯乙酸乙酯magnesium sulfate 、 SiO2 、 hexanes 作用下, 以 乙醇 为溶剂, 反应 0.33h, 以to give the desired product (181 mg, 1.8%)的产率得到imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester
    参考文献:
    名称:
    Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same
    摘要:
    本发明提供了式(4)的化合物及其药学上可接受的盐和溶剂化物,它们可用作丙型肝炎病毒(HCV)聚合酶酶的抑制剂,并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含式(4)的化合物、它们的药学上可接受的盐和溶剂化物的制药组合物。此外,本发明还提供了用于制备式(4)的化合物的中间体和方法。
    公开号:
    US20090281122A1
点击查看最新优质反应信息

文献信息

  • Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:US07151105B2
    公开(公告)日:2006-12-19
    The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    本发明提供了公式(4)的化合物及其药学上可接受的盐和溶剂,它们可用作丙型肝炎病毒(HCV)聚合酶酶的抑制剂,并且对于治疗HCV感染的HCV感染哺乳动物也很有用。本发明还提供了包括公式(4)的化合物、其药学上可接受的盐和溶剂的制药组合物。此外,本发明还提供了制备公式(4)化合物的中间体化合物和有用方法。
  • INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
    申请人:Gonzalez Javier
    公开号:US20070015764A1
    公开(公告)日:2007-01-18
    The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    本发明提供了公式(4)的化合物及其药学上可接受的盐和溶剂,这些化合物可用作丙型肝炎病毒(HCV)聚合酶酶的抑制剂,并且还可用于治疗HCV感染的HCV感染哺乳动物。本发明还提供了包含公式(4)的化合物、其药学上可接受的盐和溶剂的制药组合物。此外,本发明还提供了中间体化合物和制备公式(4)的方法。
  • Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same
    申请人:Gonzalez Javier
    公开号:US20090281122A1
    公开(公告)日:2009-11-12
    The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    本发明提供了式(4)的化合物及其药学上可接受的盐和溶剂化物,它们可用作丙型肝炎病毒(HCV)聚合酶酶的抑制剂,并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含式(4)的化合物、它们的药学上可接受的盐和溶剂化物的制药组合物。此外,本发明还提供了用于制备式(4)的化合物的中间体和方法。
  • US7151105B2
    申请人:——
    公开号:US7151105B2
    公开(公告)日:2006-12-19
  • US7622605B2
    申请人:——
    公开号:US7622605B2
    公开(公告)日:2009-11-24
查看更多

同类化合物

咪唑并[1,2-b][1,2,4]三唑并[4,3-D][1,2,4]三嗪 3-甲基咪唑并[1,2-b][1,2,4]噻嗪 3-溴-7-甲基咪唑并[1,2-b][1,2,4]三嗪 3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇 2-(3-溴咪唑并[1,2-b][1,2,4]-7-三嗪)丙烷-2-醇 3-(3-methylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2-imidazo[1,2-b][1,2,4]triazin-3-ylpropan-2-ol hydrochloride 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol 2-(2,4-difluorophenyl)-6-((pyridin-2-yloxy)methyl)imidazo[1,2-b][1,2,4]triazine 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine 7-Bromo-2-methylimidazo[1,2-b][1,2,4]triazine 1,2,3,4-tetrahydro-dibenzo[4,5:e]imidazo[1,2-b][1,2,4]triazine 2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester 2-(imidazo[1,2-b][1,2,4]triazin-6-yl)ethanol 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b][1,2,4]triazine 7,9-Dimethylimidazo[1,2-b][1,2,4]benzotriazine 7-Methylimidazo[1,2-b][1,2,4]benzotriazine 7-Methoxyimidazo[1,2-b][1,2,4]benzotriazine imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde 3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b][1,2,4]triazin-7-amine 7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine Imidazo[1,2-b][1,2,4]triazin-2(1H)-one 6-(3-Methoxycyclohexyl)-2-phenylimidazo[1,2-b][1,2,4]triazine 3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2,3-diphenyl-6-thiophen-2-yl-imidazo[1,2-b][1,2,4]triazine 7-(2-chloropyridin-4-yl)-3-trifluoromethylimidazo[1,2-b][1,2,4]triazine 3-(1-fluoro-1-methylethyl)imidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 6-(5-Chlorothiophen-2-yl)-2,3-dimethylimidazo[1,2-b][1,2,4]triazine 6-(5-Bromothiophen-2-yl)-2,3-dipyridin-2-ylimidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-ethyl-2-ethylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 2-(5-{7-[2-(difluoromethoxy)benzyl]-6-methylimidazo[1,2-b][1,2,4]triazin-2-yl}-pyrimidin-2-yl)propan-2-ol 2-[2-Chloro-4-[2-[2-cyclopentyl-5-(imidazo[1,2-b][1,2,4]triazin-6-ylmethyl)-4,6-dioxooxan-2-yl]ethyl]phenyl]-2-methylpropanenitrile (7E)-3-methyl-2-methylidene-7-[(2,3,4-trimethoxyphenyl)methylidene]-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(2-chloro-6-fluorophenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (3Z)-3-[(3-methoxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12Z)-12-[(2,4-dichlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(4-chlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (3E)-3-(thiophen-2-ylmethylidene)-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[[4-(dimethylamino)phenyl]methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (7E)-7-[(2-methoxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(3,4-dihydroxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[(3,4,5-trimethoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(2-methoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one 2-(Azepan-1-yl)-3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-b][1,2,4]triazine 4-[(11-Hydroxy-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-12-yl)methylidene]-2-methoxycyclohexa-2,5-dien-1-one 2-(1-Adamantyl)-6,7,8,9-tetrahydroimidazo[1,2-b][1,2,4]benzotriazine 6-[1-(Furan-2-ylmethyl)-2,5-dimethylpyrrol-3-yl]-2,3-diphenylimidazo[1,2-b][1,2,4]triazine